NRG Oncology

The phase 3 ARCHER trial (NRG-GU015) is now enrolling 486 patients to compare ultra-hypofractionated stereotactic body radiation therapy (5 treatments) versus standard hypofractionated radiotherapy (20 treatments) for muscle invasive bladder cancer.

The NRG-BR003 phase 3 trial found that adding carboplatin to standard paclitaxel and doxorubicin/cyclophosphamide chemotherapy did not provide statistically significant improvements in survival outcomes for triple-negative breast cancer patients.

The NRG-NSABP B-51/RTOG 1304 trial found that regional nodal irradiation does not reduce invasive breast cancer recurrence in patients whose axillary nodes converted from positive to negative after neoadjuvant chemotherapy.

• Flatiron Health and NRG Oncology have partnered to implement Flatiron Clinical Pipe, an EHR-to-EDC connector technology, in a multi-center oncology trial to enhance data entry efficiency. • The technology enables rapid transfer of thousands of data points directly from electronic health records, eliminating the need for source data verification and potentially reducing administrative burden on research staff. • A correlative study will be conducted alongside the implementation to evaluate the efficiency of Flatiron Clinical Pipe compared to traditional data entry methods in clinical trials.

Cortechs.ai and EDAP TMS SA achieved a milestone with the first-ever OnQ Prostate-assisted Focal One Robotic HIFU procedure performed at UCSF Prostate Center.

Financial hardship affects 50-70% of cancer patients in community settings, leading to treatment adherence issues and worse outcomes, particularly among underserved populations.

A phase II trial (NRG-RTOG1106/ECOG-ACRIN 6697) investigated whether midtreatment FDG-PET/CT-guided adaptive radiation therapy (RT) could improve outcomes in stage III non-small cell lung cancer (NSCLC).

A phase II trial evaluated stereotactic body radiotherapy (SBRT) to the primary lung tumor followed by chemoradiotherapy and consolidation immunotherapy in locally advanced NSCLC.

Adjuvant tamoxifen significantly reduces the 15-year risk of ipsilateral breast cancer recurrence in patients with good-risk DCIS who forgo radiation therapy.

The NRG Oncology/Alliance LU005 trial found that adding atezolizumab to standard chemoradiotherapy (CRT) did not significantly improve overall survival in patients with limited-stage small-cell lung cancer (LS-SCLC).